Serial changes in platelet activation biomarkers and the effects of anti-platelet therapy in percutaneous coronary intervention

我们研究了CYP2C19基因变异对接受择期经皮冠状动脉介入治疗(PCI)患者的血小板功能检测以及凝血激活和炎症生物标志物的影响。在接受氯吡格雷治疗的患者中，只有非氯吡格雷残留的血小板聚集与CYP2C19降低的功能等位基因相关。这些血小板功能检测可能有助于确定CYP2C19功能降低基因变异体的携带者，并监测择期经皮冠状动脉介入治疗患者双重抗血小板治疗的疗效。

We investigated the effects of CYP2C19 gene variants on platelet function tests and biomarkers of coagulation activation and inflammation in patients undergoing elective percutaneous coronary intervention(PCI). Only on-clopidogrel residual platelet aggregation was associated with the CYP2C19-reduced function allele in patients treated with clopidgrel. These platelet function tests may be useful for identifying carriers of CYP2C19 reduced-function gene variants and monitoring the efficacy of dual antiplatelet therapy in patients undergoing elective PCI.